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Exporting “failure”: why 
research from rich countries 
may not benefi t the 
developing world
Exportando “fracasso”: porquê a 
pesquisa de países desenvolvidos 
pode não benefi ciar os países 
em desenvolvimento
ABSTRACT
The ‘10/90 gap’ was fi rst highlighted by the Global Forum for Health Research. 
It refers to the fi nding that 90% of worldwide medical research expenditure is 
targeted at problems affecting only 10% of the world’s population. Applying 
research results from the rich world to the problems of the poor may be a 
tempting, potentially easy and convenient solution for this gap. This paper 
had the objective of presenting arguments that such an approach runs the risk 
of exporting failure. Health interventions that are shown to be effective in the 
specifi c context of a Western industrialized setting will not necessarily work 
in the developing world.
DESCRIPTORS: Descriptors: Biomedical Research, trends. Technical 
Cooperation. Developed Countries. Developing Countries. Evidence-
Based Medicine.
RESUMO
O “gap 10/90” foi inicialmente apontada pelo Global Forum for Health 
Research. Refere-se ao achado de que 90% dos gastos mundiais em pesquisa 
médica é voltada a problemas que afetam apenas 10% da população mundial. 
Resultados de pesquisa aplicáveis provenientes dos países ricos aos problemas 
dos pobres poderiam ser uma solução tentadora, conveniente e potencialmente 
fácil para solução desse gap. O artigo teve por objetivo apresentar argumentos 
de que tal abordagem acarretaria o risco de exportar fracassos. Intervenções 
em saúde que se mostram efetivas no contexto específico de um país 
ocidental industrializado necessariamente não funcionará em um país em 
desenvolvimento.
DESCRITORES: Pesquisa Biomédica, tendências. Cooperação Técnica. 
Países Desenvolvidos. Países em Desenvolvimento. Medicina Baseada 
em Evidências.
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The “10/90 gap” was fi rst highlighted by the Global 
Forum for Health Research.a It refers to the fi nding 
that 90% of worldwide medical research expenditure is 
targeted at problems affecting only 10% of the world’s 
population. Applying research results from the rich 
world to the problems of the poor may be a tempting, 
potentially easy and convenient solution for this gap. 
In this paper, we argue that such an approach runs 
the risk of exporting failure. Health interventions that 
are shown to be effective in the specifi c context of a 
Western industrialized setting will not necessarily work 
in the developing world.5,9
PROBLEMS WITH RANDOMIZED 
CONTROLLED TRIALS
Randomized controlled trials are considered to be the 
gold standard in assessing health interventions, yet they 
generally only investigate one intervention at a time.19,20 
As we shift from an era of classic chronic disease or risk 
factor epidemiology to one of “eco-epidemiology”,18 
in which the focus is on prevention of disease through 
governance and fi scal and environmental policies rather 
than on simplistic notions of individual lifestyle modi-
fi cation, different approaches to research are needed. 
As Schwartz & Carpenter15 pointed out, focusing on 
individual-level health determinants while ignoring 
more important macro-level determinants is equivalent 
to obtaining the right answer to the wrong question.
A further limitation of randomized trials is that their 
results are highly dependent upon their context, which 
affects the appropriateness, interpretation, and external 
validity of the study.21 Many randomized trials study 
highly selected groups of people, which means that the 
results may not be applicable to the broader population, 
resulting in a confl ict between proof of concept and 
external validity.11 Trials often fail to take into account 
whether the intervention, if found to be effective, would 
be affordable to the vast majority who should benefi t 
from such intervention.
PROBLEMS WITH SYSTEMATIC REVIEWS
Systematic reviews are another tool for evaluating the 
quality of clinical evidence relating to a health interven-
tion. Research output derived from similar interven-
tions or studies with similar outcomes are evaluated in 
aggregation to assess whether, if pooled together, the 
data would show more consistent results than in the 
individual studies. Systematic reviews are a powerful 
tool in that they maximize the data and evidence avail-
able, thus reaching conclusions based on stronger data 
quality and quantity.
INTRODUCTION
a Global Forum for Health Research. 10/90 report on health research 1999. [cited 2009 Dec 02] Available from: www.globalforumhealth.org/
Media-Publications/Publications/10-90-Report-on-Health-Research-1999
However, systematic reviews also suffer from 
contextual problems similar to those of trials. Most 
of the studies that are included in such reviews come 
from particular contexts, which are often developed 
country settings. Thus, the fi ndings from systematic 
reviews may not always be applicable or relevant to 
other settings.17 As Chinnock et al2 stated, “systematic 
reviews have yet to achieve their potential as a resource 
for practitioners in developing countries”.2
ENABLING RESEARCH PRACTICES 
AND STANDARDS THAT ENHANCE THE 
APPLICATION OF RESEARCH FINDINGS IN 
THE DEVELOPING WORLD
Given these limitations of randomized controlled trials 
and systematic reviews, can the results from such 
studies in the developed world ever be applicable to the 
developing world? It should be stressed that researchers 
based in developing countries and actively involved in 
generating systematic reviews and conducting clinical 
trials will have a different perspective on contextual 
factors, the relevance of the research question and the 
applicability of their fi ndings. The importance of this 
type of evidence has not been discussed. Here, a few 
examples of the valuable contributions that such studies 
can make towards other, developing country settings 
are highlighted below.
Firstly, the validity of such work across differing commu-
nities should be rigorously assessed to see whether their 
results are deemed generalizable. Secondly, studies can 
potentially be of more use if they take into account 
different contexts such as the organization of healthcare 
delivery, its human resources and fi nancing. Regional 
differences can strengthen a multinational study, and 
do not weaken it if an appropriate analysis plan is 
integrated early on in designing the work. Two major 
international research projects have demonstrated this: 
the MRC CRASH trial,14 which evaluated the role of 
corticosteroids among patients with head injury; and 
the INTERHEART study,23 a large case-control study 
on risk factors associated with myocardial infarction. 
These studies included research teams from various 
contexts, thereby generating knowledge that was 
relevant and applicable to local settings.
Until such large collaborative initiatives become 
the norm, we should acknowledge the limitations of 
our current best evidence. Systematic reviews, for 
instance, need to present all the sound evidence on the 
study subject, but should conclude with take-home 
messages on the circumstances under which they may 
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or may not work. Such simple messages could alert the 
reader regarding the external validity of the conclu-
sions reached and the type of setting within which 
such evidence may yield a higher impact. It is also 
essential that context-appropriate health research and 
health interventions take place in developing countries. 
Exporting research results and intervention methods 
purely based on industrialized countries’ settings, to 
poorer countries, ignores the fact that the expectations, 
costs and burdens of disease vary widely between these 
countries. The Cochrane Collaboration’s health promo-
tion and public health group, in collaboration with an 
international taskforce, has recently completed a study 
to make recommendations for systematic reviews on 
public health topics of particular relevance to devel-
oping countries.13 Such recommendations will aid in 
identifying topics or fi elds in which a synthesis of 
the evidence may be of greater benefi t for developing 
countries. Again, more of this evidence needs to hail 
from the part of the world where many of the global 
health problems are concentrated, in order to ensure 
truly systematic, global evidence-based medicine.
BARRIERS TO RESEARCH IN THE DEVELOPING 
WORLD
Lack of access to the research literature limits research 
efforts. A United Nations report presented in Addis 
Ababa in 1969 proposed that if the “vicious circle of 
underdevelopment” was to be overcome, an indig-
enous scientifi c capability needed to be fostered, which 
meant overcoming the “highly imperfect access to the 
body of world scientifi c knowledge”.3 The current 
status quo of restricted access means that the scien-
tifi c conversation between people in the rich and poor 
worlds – conversations in which clinical evidence is 
critiqued or new clinical trial reports are used to set 
policy – is an unequal one. “Authors from developing 
countries,” according to Langer et al,10 “are often not 
adequately prepared to participate in the international 
scientifi c debate, as they have limited access to the 
published literature.”10 The HINARIa program, set up 
by WHO together with major publishers, is an example 
of a project that is producing a positive change, since it 
enables health institutions in 113 developing countries 
to gain access to over 3,750 journal titles.
In addition to access to literature, many other issues can 
be listed as critical obstacles. The limited research – in 
terms of quantity and impact – arising from developing 
countries is also partly due to the poor academic envi-
ronments. Academics in developing countries often 
work in isolated settings, and fewer of them interact 
with public health policy makers. They often work 
under extreme pressure in terms of clinical caseload, 
and economic concerns mean that their spare time is 
devoted to private practice. In the same vein, issues of 
changing the research culture, investment in research 
skills and funding of research also appear as funda-
mental and important barriers to research activity in 
developing countries. Also, the most prominent medical 
journals, mostly based in the developed world, appear 
to be less concerned with geographically and economi-
cally distant healthcare issues.8,16
Academic and research collaborations based in 
developing countries need to address local issues and 
produce research that can be easily and readily imple-
mented locally. Furthermore, there is a huge, untapped 
potential for research in less developed countries to 
contribute to medicine and public health in general 
by generating low-cost solutions to health problems, 
some of which are also crippling the economies of 
rich countries despite their much greater spending on 
health. Such work may export success from the poor 
world to the rich world.
STRATEGIES TO ENCOURAGE ACCESS TO 
RESEARCH RESULTS AND RESEARCH CAPACITY 
IN DEVELOPING COUNTRIES
Chronic barriers to research in developing worlds need 
to be addressed through a formal organizational struc-
ture to sustain collaboration. We must invite academics 
from the developing world to sit at the academic high 
table to offer their views on what work is needed. This 
will perhaps shape how all researchers, from both rich 
and poor worlds, frame their own papers by encour-
aging thinking of a more globalized nature. To tackle 
the growing inequalities in global health and raise the 
profi le of international health in developed countries, 
such novel approaches are needed.
One example is the “NHS links” (Wright et al22), a 
network of health professionals across the United 
Kingdom involved in a variety of health links between 
NHS trusts and health centers in less developed 
countries. Wright, its medical director, argues that a 
“coherent and systematic approach to international 
exchanges would not only promote a more professional 
and equitable approach to the selection and induction of 
staff, but would also place global health and inequalities 
in the conscience of health organizations themselves”.22 
Such links would mean the ‘quality threshold’ for 
research would not need to be lowered.
The International Dialogue on Evidence-informed 
Action to Achieve Health Goals in Developing 
Countries (IDEAHealthb) is a forum that focuses on 
a World Health Organization, The HINARI Programme. [cited 2009 Dec 02] Available from: http://www.who.int/hinari/en/
b World Health Organization. International Dialogue on Evidence-informed Action to Achieve Health Goals in Developing Countries. [cited 
2009 Dec 02] Available from: http://www.who.int/rpc/meetings/ideahealth/en/index.html
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a small number of important health goals, bringing 
together health policy-makers, researchers and citizen-
consumers to share experiences and evidence in a bid 
to formulate solutions on how to respond to challenges 
like health human resources, maternal and child health 
and health fi nancing.
FINAL CONSIDERATIONS
There is a lack of research funding into low-tech inter-
ventions with the potential to yield important scientifi c 
and public health advances. This yield refers not only 
to clinical end-points but also to cost-effectiveness 
measures, among others. We should study low-tech 
interventions especially if they produce high yields in 
the appropriate settings. There are several examples 
of successful low-tech health interventions that have 
been studied in resource-limited settings, such as 
management of depression1 treatment of seizures 
due to neurocysticercosis,6 rapid diagnostic tools for 
tuberculosis,12 and use of web resources to prevent 
sexually transmitted infections.4
As for policy-formulating evidence, reality shows 
well-documented and signifi cant gaps between ‘what 
is known’ and ‘what is done’.a Health differentials 
between social groups, or between poor and rich coun-
tries, are not primarily generated by medical causes, and 
they require solutions at a different level.
When approaching the evidence using a low and 
middle-income perspective, researchers need to be 
aware of context, i.e. where it comes from. In particular, 
they need to assess whether the evidence is relevant 
to their own setting. A true evidence-based approach 
towards global international health requires that the 
research and academic community from low and 
middle-income settings should have a major say in the 
shaping of interventions that address their own needs.
a Global Forum for Health Research. 10/90 report on health research 1999. [cited 2009 Dec 02] Available from: www.globalforumhealth.org/
Media-Publications/Publications/10-90-Report-on-Health-Research-1999
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